Logo image of AKTS

AKTIS ONCOLOGY INC (AKTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AKTS - US00973N1028 - Common Stock

21.22 USD
-0.4 (-1.85%)
Last: 1/27/2026, 8:00:00 PM
21.12 USD
-0.1 (-0.47%)
After Hours: 1/27/2026, 8:00:00 PM
Fundamental Rating

1

Taking everything into account, AKTS scores 1 out of 10 in our fundamental rating. AKTS was compared to 123 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of AKTS have multiple concerns. While showing a medium growth rate, AKTS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year AKTS has reported negative net income.
  • AKTS had a negative operating cash flow in the past year.
  • AKTS had negative earnings in each of the past 5 years.
  • In the past 5 years AKTS always reported negative operating cash flow.
AKTS Yearly Net Income VS EBIT VS OCF VS FCFAKTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • AKTS's Return On Assets of -268.85% is on the low side compared to the rest of the industry. AKTS is outperformed by 94.31% of its industry peers.
Industry RankSector Rank
ROA -268.85%
ROE N/A
ROIC N/A
ROA(3y)-106.7%
ROA(5y)-81.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTS Yearly ROA, ROE, ROICAKTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

  • AKTS's Gross Margin of 15.97% is on the low side compared to the rest of the industry. AKTS is outperformed by 70.73% of its industry peers.
  • AKTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTS Yearly Profit, Operating, Gross MarginsAKTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

0

2. Health

2.1 Basic Checks

  • AKTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AKTS has been increased compared to 1 year ago.
  • The number of shares outstanding for AKTS has been increased compared to 5 years ago.
  • The debt/assets ratio for AKTS is higher compared to a year ago.
AKTS Yearly Shares OutstandingAKTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
AKTS Yearly Total Debt VS Total AssetsAKTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • AKTS has an Altman-Z score of 1.68. This is a bad value and indicates that AKTS is not financially healthy and even has some risk of bankruptcy.
  • AKTS has a worse Altman-Z score (1.68) than 71.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.68
ROIC/WACCN/A
WACC8.74%
AKTS Yearly LT Debt VS Equity VS FCFAKTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 0.32 indicates that AKTS may have some problems paying its short term obligations.
  • With a Current ratio value of 0.32, AKTS is not doing good in the industry: 95.12% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.28 indicates that AKTS may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.28, AKTS is doing worse than 95.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.32
Quick Ratio 0.28
AKTS Yearly Current Assets VS Current LiabilitesAKTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

6

3. Growth

3.1 Past

  • The earnings per share for AKTS have decreased strongly by -49.48% in the last year.
  • AKTS shows a small growth in Revenue. In the last year, the Revenue has grown by 2.97%.
  • Measured over the past years, AKTS shows a very strong growth in Revenue. The Revenue has been growing by 80.23% on average per year.
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85%
Revenue 1Y (TTM)2.97%
Revenue growth 3Y60.53%
Revenue growth 5Y80.23%
Sales Q2Q%28.92%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.01% on average over the next years. This is a very strong growth
  • AKTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.27% yearly.
EPS Next Y42.58%
EPS Next 2Y20.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.7%
Revenue Next 2Y34.27%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AKTS Yearly Revenue VS EstimatesAKTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
AKTS Yearly EPS VS EstimatesAKTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AKTS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTS Price Earnings VS Forward Price EarningsAKTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTS Per share dataAKTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AKTS's earnings are expected to grow with 20.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.01%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • AKTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

AKTIS ONCOLOGY INC / AKTS FAQ

What is the ChartMill fundamental rating of AKTIS ONCOLOGY INC (AKTS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AKTS.


What is the valuation status for AKTS stock?

ChartMill assigns a valuation rating of 1 / 10 to AKTIS ONCOLOGY INC (AKTS). This can be considered as Overvalued.


How profitable is AKTIS ONCOLOGY INC (AKTS) stock?

AKTIS ONCOLOGY INC (AKTS) has a profitability rating of 0 / 10.


What is the financial health of AKTIS ONCOLOGY INC (AKTS) stock?

The financial health rating of AKTIS ONCOLOGY INC (AKTS) is 0 / 10.